BioSpace News Archive

Ethris GmbH and Heqet Therapeutics announced a collaboration agreement to harness the potential of ncRNA for heart tissue regeneration following acute myocardial infarction and in heart failure.

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the strategic strengthening of its medtech acceleration team with the appointment of Mano Iyer as Partner and the promotion of Cécile Dupont to Partner.

Medivir AB announced that clinical data from the ongoing phase 1b/2a study of in fostroxacitabine bralpamide in combination with Lenvima® in hepatocellular carcinoma, will be presented at the ASCO Gastrointestinal Cancers Symposium, January 18-20, 2024 in San Francisco, USA.

Enterome announced it will present updated efficacy data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in patients with first progression/recurrence of glioblastoma, in an oral presentation at the Society for Neuro-Oncology 28th Annual Meeting which will be held in Vancouver, British Columbia, Canada on November 15-19, 2023.

KalVista Pharmaceuticals, Inc. provided clinical trial and regulatory updates for its lead program sebetralstat, in development as a potential oral on-demand therapy for hereditary angioedema.

Zura Bio Limited a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced its financial results for the quarter ended September 30, 2023, and recent business highlights.

Gyre Therapeutics announced the presentation of a poster at the American Association for the Study of Liver Diseases’ Annual Liver Meeting, November 10-14, 2023, in Boston, Massachusetts.

Acumen Pharmaceuticals, Inc. reported financial results for the third quarter of 2023 and provided a business update.

Akero Therapeutics, Inc. reported third quarter financial results for the period ending September 30, 2023 and provided business updates.

Bio-Techne Corporation announced that it will present at the following investor conferences.